Previous Close | 24.56 |
1-Year Change | 1206.38% |
6-Months Change | 541.25% |
3-Months Change | 214.87% |
Moving Avg (50d) | 13.362 |
Moving Avg (200d) | 6.723 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 17.1B |
Beta (3-Years) | 0.32 |
Revenue Growth (ttm) | -100% |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -273.53% |
EPS (ttm) | -1.52 |
PE Ratio (ttm) | -16.16 |
Dividend Yield | % |
Asset Description: | Summit Therapeutics Inc. |
Predicted Direction: | Buy |
Signal Strength: | Strong buy |
Forecast Date: | 2024-09-09 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
24.069 | 23.332 | 22.841 | 22.104 | 20.876 | 19.648 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |